- David Jones
- 3 days ago
- 5 min read
Practical insights for sponsors, CROs, and biotech teams on implementing risk-based quality management in early phase studies, drawn from a live COG UK session with Duncan Hall, CEO of TRI.
Why Early Phase RBQM Demands a Fresh Approach
The session featured Duncan Hall, CEO at TRI, speaking with David Jones, Head of Content at The PBC Group, during a keynote recorded live at COG UK. Duncan Hall’s expertise spans operational technology for clinical trials, with a focus on practical solutions that address real-world needs.
The discussion centered on the evolving requirements for risk-based quality management (RBQM) in early phase clinical development, particularly in light of recent regulatory updates. Attendees included pharma, biotech, CRO, and clinical ops leaders, many grappling with new expectations for patient-centricity, validated systems, and central review within small studies.
From Checkbox Monitoring to Critical Thinking: The Evolution of RBQM
For decades, monitoring in clinical trials followed a site-focused, checkbox model, emphasizing routine verification, source data checks, and regulatory compliance, but often lacking meaningful risk assessment or prioritization. Duncan Hall stressed that modern RBQM starts well before site visits or database lock, it begins with protocol design and a deliberate analysis of study risks and critical data.
Protocol Risk Assessment: Today's RBQM asks clinical teams to identify what matters most, what data will drive the outcome, impact patient safety, or threaten study integrity. By focusing on critical-to-quality factors during protocol development, sponsors and CROs can embed risk management into operations rather than bolting it on later.
This approach is now codified in regulatory guidance, including recent GCP updates, meaning that RBQM is not optional but integral for any clinical stage trial.
What matters for you: RBQM is shifting from procedural compliance to operational mindset; protocol risk assessment should be an active tool guiding study conduct and decisions.
Early Phase Challenges: Rethinking Analytics and Priorities
While RBQM is widely accepted and applied in late-phase (Phase 3) studies, with robust central monitoring, site comparisons, and data surveillance, early phase trials present unique obstacles:
Limited Patient Numbers and Site Comparisons
Early phase studies often run with single or very few centers, and small patient cohorts. Traditional site-by-site analytics break down, comparisons across sites or regions yield little actionable insight.
In some rare disease settings, one patient per site is common, making the patient the relevant unit for monitoring and risk assessment.
Patient-Centric Approach
The operational lens in early phase shifts from site performance to individual patient journeys. Teams need to understand and track patient-level risk, event timelines, and clinical changes.
Budgets tend to be smaller, reducing access to enterprise systems and pushing teams toward manual tools like spreadsheets and email, a compliance risk under updated GCP requirements, which now mandate validated technology and audit trails.
Technology Fit and Compliance Issues
Existing central monitoring solutions were designed for large, multi-site studies. Applying them to early phase is often inefficient, cumbersome, or non-compliant.
Many teams fall back on shortcut methods, risking data quality, missed signals, and inspection complications.
For clinical ops and vendor teams: Early phase studies demand purpose-built, patient-focused tools and workflows. Ensure technology can aggregate all relevant data, enable central review, and provide compliance essentials (audit trails, access control).
Building Practical RBQM Systems: Lessons from Real-World Application
After extensive market research, including interviews with medical reviewers and trial safety monitors, Duncan Hall and his team at TRI found wide variability in early phase oversight practices. Few organizations had standardized, efficient workflows. Key pain points included:
Fragmented Data Sources: Early phase trials often involve 3–5 separate data streams (demographics, endpoints, operational status, etc.), complicating review.
Inefficient Review Cycles: Data was manually checked multiple times, costing money and creating gaps where critical signals might be missed.
Lack of Audit Trails: Manual reviews lacked documented oversight, putting teams at risk for inspection findings.
To address these, TRI released a module designed for early phase RBQM, focusing on:
Aggregating subject-level data for a holistic view of each patient’s journey.
Prioritizing reviews, flagging subjects needing deeper dives (e.g., those with new or multiple adverse events).
Enabling efficient, documented reviews and collaboration, flagging and tagging reviewed subjects to prevent redundant work.
Providing easy report generation for trial master file documentation.
Supporting real-world data aggregation and critical signals identification.
Operational focus: Standardize review processes, capture learnings, and leverage technology that can adapt to evolving data streams and team structures.
Managing RBQM Technology Costs for Small Budgets
Technology provision in clinical trials comes with baseline costs, security, hosting, privacy, and compliance. For early phase studies and small biotechs, this is a real concern.
David Jones and Duncan Hall discussed strategies to balance operational efficiency and budget constraints:
Vendors can offer flexible pricing models, accepting lower margins to build early partnerships and enable wider adoption.
Sponsors should seek solutions scalable from early phase to later stage, allowing for cost-effective upgrades and continuity.
Data re-use is key: Structured RBQM outputs from Phase 1 can inform future study designs, enable smoother transitions, and support regulatory submissions.
For outsourcing leads: Engage vendors early and ask about partnership models. Demand a clear plan for scaling solutions across phases and sites.
What This Means in Practice
Design RBQM into your protocol from the start; focus on what is critical-to-quality and patient safety.
Shift from site-level analytics to patient-centric review and risk assessment in early phase studies.
Audit your manual processes, ensure they meet the latest GCP requirements for technology, access control, and documentation.
Aggregate all study data in a single, validated platform for efficient oversight and operational clarity.
Tag and document all reviews to avoid repetitive work and missed signals.
Use technology purpose-built for early phase studies, not repurposed late-phase solutions.
Negotiate vendor arrangements that allow for budget flexibility and future scaling.
Key Takeaways
RBQM is now a regulatory requirement for all clinical stage trials, including early phase, under updated GCP guidance.
Early phase studies need patient-level central review, not site-by-site comparisons, requiring new operational approaches.
Manual review cycles, spreadsheets, and email are no longer sufficient; validated systems and streamlined workflows are essential.
Efficient central monitoring in early phase improves quality, reduces risk of missed signals, and saves both time and budget.
Technology and vendor partnerships should be adaptable, supporting both small-budget trials and future expansion.
Selected Quotes
"RBQM encourages us to think much more critically right from the beginning of protocol design…what are the risks to this protocol, what could impact the collection, the reliable collection of data, what could impact the safety of the patients, and what really matters." — Duncan Hall
"When we're thinking about early phase monitoring, the lens…is very different. We're really trying to understand what's going on in the study…from a patient perspective, the journey of those individual patients." — Duncan Hall
"Data gets reviewed, then it gets passed on, then it gets reviewed again…it's incredibly inefficient. It's costing the industry huge amounts of money for a low or no value labor-intensive process." — Duncan Hall
"The need for RBQM on early phase studies…I think, is much greater just because of the amount of unknowns and the amount of risk…technology needs to be for purpose, designed specifically for early phase studies." — Duncan Hall
Links & References
· For more insights and resources on clinical trial operations and outsourcing, visit The PBC Group: https://thepbcgroup.com
· ICH E6(R3) Guidance – Latest regulatory guidance on GCP and RBQM
· TRI – TRI company site and technology solutions for clinical trials
By centering on risk, efficiency, and patient-specific review in early phase clinical trials, sponsors and CROs can meet rising expectations for data quality, operational excellence, and regulatory compliance—ensuring a robust foundation for future clinical development.
Comments